Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.

Despite the recent publication of calreticulin (CALR)-mutated essential thrombocythemia (ET) management guidelines by the European Leukemia Net (ELN), there remains a paucity of data regarding the optimal way to manage this condition. To determine practice around Australia, we constructed a survey asking investigation and treatment questions in a hypothetical case of a young woman with CALR-mutated ET and subsequent progression to myelofibrosis. 51 of 88 hematologists replied. The responses demonstrated significant heterogeneity in specific issues such as the use of aspirin, when to initiate cytoreduction, the preferred type of cytoreduction, and platelet targets. These observations support the ELN acknowledgment that a strong evidence base for many management recommendations is lacking in this disease, and that substantial further research is needed.

[1]  P. Cony-Makhoul,et al.  Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. , 2021, Blood advances.

[2]  Belinda B. Guo,et al.  Myeloid somatic mutation panel testing in myeloproliferative neoplasms. , 2021, Pathology.

[3]  T. Barbui,et al.  Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. , 2020 .

[4]  B. Bellosillo,et al.  Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia , 2020, British journal of haematology.

[5]  V. Skov.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses , 2020, Cancers.

[6]  D. Birnbaum,et al.  Targeted molecular characterization shows differences between primary and secondary myelofibrosis , 2020, Genes, chromosomes & cancer.

[7]  M. Griesshammer,et al.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet , 2018, Leukemia.

[8]  T. Barbui,et al.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.

[9]  P. Cony-Makhoul,et al.  Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study , 2017, Haematologica.

[10]  F. Passamonti,et al.  Update from the latest WHO classification of MPNs: a user's manual. , 2016, Hematology. American Society of Hematology. Education Program.

[11]  M. Cazzola,et al.  Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group , 2016, American journal of hematology.

[12]  M. Griesshammer,et al.  Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation , 2016, Haematologica.

[13]  V. Vicente,et al.  Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation , 2016, British journal of haematology.

[14]  T. Barbui,et al.  Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia , 2015, Blood Cancer Journal.

[15]  A. Tefferi,et al.  Calreticulin mutations and long-term survival in essential thrombocythemia , 2014, Leukemia.

[16]  B. Bellosillo,et al.  Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia , 2011, British journal of haematology.

[17]  T. Barbui,et al.  Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. , 2010, Blood.

[18]  R. Mesa,et al.  Estrogen‐based hormone therapy and thrombosis risk in women with essential thrombocythemia , 2006, Cancer.

[19]  T Giorgino,et al.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.

[20]  Peter J Campbell,et al.  Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.